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Efﬁcacy of a Weight Loss Intervention for African American
Breast Cancer Survivors
Melinda Stolley, Patricia Sheean, Ben Gerber, Claudia Arroyo, Linda Schiffer, Anjishnu Banerjee, Alexis Visotcky,
Giamila Fantuzzi, Desmona Strahan, Lauren Matthews, Roxanne Dakers, Cynthia Carridine-Andrews, Katya
Seligman, Sparkle Springﬁeld, Angela Odoms-Young, Susan Hong, Kent Hoskins, Virginia Kaklamani, and Lisa Sharp
A B S T R A C T
Purpose
African American women with breast cancer have higher cancer-speciﬁc and overall mortality rates.
Obesity is common among African American women and contributes to breast cancer progression
and numerous chronic conditions. Weight loss interventions among breast cancer survivors pos-
itively affect weight, behavior, biomarkers, and psychosocial outcomes, yet few target African
Americans. This article examines the effects of Moving Forward, a weight loss intervention for
African American breast cancer survivors (AABCS) on weight, body composition, and behavior.
Patients and Methods
Early-stage (I-III) AABCS were randomly assigned to a 6-month interventionist-guided (n = 125) or
self-guided (n = 121) weight loss program supporting behavioral changes to promote a 5% weight
loss. Anthropometric, body composition, and behavioral data were collected at baseline, post-
intervention (6 months), and follow-up (12 months). Descriptive statistics and mixed models an-
alyses assessed differences between groups over time.
Results
Mean (6 standard deviation) age, and bodymass indexwere 57.5 (6 10.1) years and 36.1 (6 6.2) kg/m2,
respectively, and 82% had stage I or II breast cancer. Both groups lost weight. Mean and per-
centage of weight loss were greater in the guided versus self-guided group (at 6 months: 3.5 kg v
1.3kg; P, .001; 3.6% v 1.4%; P, .001, respectively; at 12 months: 2.7 kg v 1.6 kg; P, .05; 2.6% v
1.6%; P, .05, respectively); 44% in the guided group and 19% in the self-guided groupmet the 5%
goal. Body composition and behavioral changes were also greater in the interventionist-guided
group at both time points.
Conclusion
The study supports the efﬁcacy of a community-based interventionist-guided weight loss program
targeting AABCS. Althoughmeanweight loss did not reach the targeted 5%, themean loss of. 3%
at 6 months is associated with improved health outcomes. Affordable, accessible health promotion
programs represent a critical resource for AABCS.
J Clin Oncol 35:2820-2828. © 2017 by American Society of Clinical Oncology
INTRODUCTION
Breast cancermortality rates are highest for African
American (AA) women, even after controlling for
demographic, diagnostic, and treatment-related
factors.1,2 All-cause mortality rates are also
higher for AA breast cancer survivors (AABCS)
due to high rates of comorbid conditions, such
as diabetes and hypertension.3-5 Ninety-two
percent of white women will survive at least
5 years after diagnosis, compared with 81%
of AA women. These differences are not eas-
ily explained and involve multiple issues; obesity
and lifestyle factors are important contributors.6,7
Evidence from a 2014 meta-analysis of 82 studies
found that prediagnosis and postdiagnosis obe-
sity was associated with higher breast cancer–
speciﬁc and overall mortality; overweight was
associated with higher overall mortality.8 Over
82% of AA women are classiﬁed as overweight/
obese, and 56.6% have obesity.9 The likelihood
of an AA woman being overweight or obese
when diagnosed with breast cancer is high.
Women often gain weight in the years after
their diagnosis, with some data suggesting AA
women gain twice as much weight as white
women.10-13
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Weight loss intervention trials with breast cancer survivors
report improvements in diet and physical activity, biomarkers of
inﬂammation and insulin resistance, and quality of life, but in-
clusion of AABCS is limited.14,15 Considering the high rates of
mortality, comorbidities, and obesity among AABCS, weight loss is
an important priority. However, due to a complex interaction of
environmental, societal, and policy-related factors, weight man-
agement may be uniquely challenging for many AAs in the United
States, particularly those with limited income.16-18 AA women are
under-represented in weight loss trials, and if they do participate,
they are more apt to drop out and lose less weight.19,20 The feasibility
of weight loss interventions for AABCS is established; however,
previous studies were underpowered and none examined body
composition.21-23We report the effects of a 6-month interventionist-
guided versus a self-guided weight loss program on anthropometric,
body composition, and behavioral outcomes in overweight/obese
AABCS postintervention and at the 12-month follow-up.
PATIENTS AND METHODS
Study Design
Moving Forward was a community-based, randomized, weight loss
intervention trial with 246 overweight/obese AABCS (Fig 1). Survivors
were recruited between September 2011 and September 2014. Detailed
methods were published previously.24
Patient Population
Eligible participants were AABCS (stages I-III), were $ 18 years of
age, had a body mass index (BMI) of $ 25 kg/m2, had completed cancer
treatment at least 6 months before recruitment (hormonal therapy
allowed), were physically able to participate in a moderate physical activity
program per health-care provider approval, and were agreeable to study
procedures. Women were excluded if they were pregnant or planning to
become pregnant during the study, taking prescription weight loss medi-
cation, or planning weight loss surgery in the coming year. Recruitment
involved direct contact by letter and phone using hospital cancer registry
contact information from three Chicago-area academic cancer centers and
community-based efforts, including referrals from oncologists, ﬂyers, social
media, and presentations. The respective institutional review boards ap-
proved all study procedures, and each participant provided written informed
consent. Women were randomly assigned using a random digit generator
after the baseline interview.
Interventions
Participants were randomly assigned to either the 6-month Moving
Forward Interventionist-Guided program (MFG) or the Moving Forward
Self-Guided program (SG). Program goals for the 6-month period were
identical: 5% weight loss achieved by decreased caloric intake (2500 kcal
daily), increased fruit and vegetable consumption, and increased physical
activity (minimum$ 150 minutes per week) on the basis of the American
Cancer Society cancer survivor guidelines.25 The cognitive-behavioral weight
loss intervention was grounded within a socioecological model26,27 to
promote self-efﬁcacy, social support, and perceived access to community-
based healthy eating and activity resources.24,28,29 To enhance its cultural
relevance, the intervention was guided by the framework of Kreuter et al30
Screened via telephone
(N = 897)
Ineligible
 BMI < 25 kg/m
 BMI too high
 Race
 No breast cancer
 DCIS/stage 0
 Stage IV
 Not 6 months post-treatment
 Moving
 Weight loss surgery in past year
 Schedule/location conflict
 Unable to exercise
 Other 
(n = 449)
(n = 67)
(n = 1)
(n = 3)
(n = 10)
(n = 26)
(n = 17)
(n = 14)
(n = 8)
(n = 1)
(n = 219)
(n = 83)
(n = 4)
Eligible, but not enrolled
 Waitlisted, did not enroll
 Lost
 Withdrew before or after interview
 Not interested 
(n = 202)
(n = 5)
(n = 12)
(n = 31)
(n = 154)
Guided weight loss program
(n = 125)
Completed 6 months
(n = 111; 88.8%)
Self-guided weight loss program
(n = 121)
Completed 6 months
(n = 101; 83.5%)
2
Completed 12 months
(n = 107; 85.6%)
Completed 12 months
(n = 100; 82.6%)
Randomly assigned
(N = 246)
Fig 1. Flow of participants through the
Moving Forward Study. BMI, body mass
index.
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using strategies that were (1) peripheral (logo, recruitmentmaterials, exercise
music); (2) evidential (evidence on health impact of breast cancer, obesity,
comorbidities in AA community); (3) constituent (intervention was de-
veloped in collaboration with AABCS; led by individuals with whom par-
ticipants could identify); and (4) sociocultural (honored values, such as the
woman’s central role in families, the importance of religion and worship and
how it affects health perspectives, heavier body image ideals, and traditional
importance of food).
MFG included twice-weekly in-person classes with supervised ex-
ercise and twice-weekly text messaging targeting enhanced self-efﬁcacy,
social support, and access to health promotion resources. Weekly Class 1
(90 minutes) began with weighing in and supervised exercise, followed by
45- to 60-minute interactive learning modules (Table 1) that addressed
knowledge (eg, relationship between obesity and cancer/health), attitudes
(eg, cancer/health fatalism), and cognitive behavioral strategies (eg, self-
monitoring, goal setting). Participants received a program binder with
hand-outs, recipes, and other supportive materials as a resource for review,
reinforcement, and reminders. Weekly Class 2 (60 minutes) was a stand-
alone 60-minute exercise class that included aerobic and resistance exercise
training. Classes were held in the evening (6-8 PM) at neighborhood
Chicago Park District facilities and were led by a study-trained community
nutritionist and exercise trainer. SG participants also received the program
binder, but no classes or text messaging. They met once with a non-
intervention staff member to receive and review program materials. At
6 months, both groups received monthly newsletters with reinforcing
information from the curriculum, news of local healthy eating and exercise
resources, and participant testimonials. The choice of the SG comparator
was based on strong feedback from our study advisory committee
(comprising disparities researchers and AABCS), referring oncologists, and
community stakeholders. A conventional usual-care or even an attention
placebo group would necessitate the withholding of lifestyle information
with known beneﬁts on health. The committee deemed this unethical and
further surmised that accrual for this community-based intervention
would be nearly impossible. Budgetary and time constraints precluded the
use of a wait-list control group.
Measurements
Anthropometric, body composition, and behavioral outcomes were
measured at baseline, 6 months, and 12 months. Height (baseline only)
was measured to the nearest 0.1 cm using a portable stadiometer (Seca,
Chino, CA). Weight was measured to the nearest 0.1 kg using a digital scale
(Tanita; Arlington Heights, IL), with participants wearing light clothes
without shoes. Two measurements for height and weight were taken;
a discrepancy of more than 0.5 cm for height or 0.2 kg for weight resulted
in a third measurement. The mean of the two most closely aligned mea-
surements were used to calculate BMI (weight [kg]/height [m2]). Waist and
hip circumference were measured with participants standing without outer
garments and with empty pockets. Waist circumference was measured to the
nearest 0.1 cm at the umbilicus during gentle expiration. Hip circumference
was recorded as the maximum circumference over the buttocks. Two
measurements were taken, with a discrepancy of more than 1 cm resulting in
a third measurement. The mean of the two measurements most closely
aligned were used for analyses. Body composition, speciﬁcally, body fat and
lean tissue mass, was measured by dual-energy x-ray absorptiometry using
the ilunar device (software version 13.6; GE, Chicago, IL).31 Dietary intake
assessment was interviewer administered using the Block 2005 Food Fre-
quencyQuestionnaire, which has been validatedwith diverse populations.32,33
Results were procured from Nutrition Quest to determine consumption of
energy, fruits and vegetables, fat, ﬁber, meat, and added sugars. Physical
activity, including the frequency and duration of moderate and vigorous
activity over the last 6 months, was measured by the Modiﬁed Activity
Questionnaire.34 Medical record abstraction and self-report questionnaires
provided information on comorbidities, breast cancer diagnosis, and treat-
ment information.
Statistical Analyses
Descriptive statistics were reported for all outcomes of interest at
baseline, including anthropometric and behavioral outcomes. Outcomes
for MFG and SG groups at various times were assessed using a linear
mixed effects model, with random effects terms to account for the
correlation in repeated measures (including baseline) from a single
woman. Interaction terms were included in the linear model to account
for differences in trend across time between groups. A compound
symmetry covariance structure was assumed for the correlation between
outcomes from the same woman across time.35,36 For each outcome,
adjusted differences in mean using the linear model, as well as estimated
standard errors for the adjusted differences, were reported. At each of the
6-month and the 12-month follow-ups, the statistical signiﬁcance of the
difference between outcomes between the MFG and SG terms was
assessed by the P value of the appropriate interaction term in the linear
model. Difference across time within the SG, as well as within the MFG,
were compared using appropriate contrast terms. An overall signiﬁcance
level of .05 was used, with multiplicity corrections wherever necessary.
All statistical analyses were performed using SAS software version 9.3
(SAS Institute, Cary, NC).
RESULTS
Participants
A total of 897 women were screened, resulting in 246
randomly assigned to MFG (n = 125) or SG (n = 121; Table 2;
Fig 1). Recruitment letters on the basis of tumor registry
Table 1. Moving Forward Weight Loss Program Weekly Topics
Week Topic
1 Obesity and lifestyle beahviors—associations with breast
cancer and overall health
2 ACS guidelines; self-monitoring and goal setting
3 Using self-monitoring tools to make better choices to meet
guidelines
4 Energy requirements; body composition—why fat matters for
cancer and overall health
5 Dealing with pain, fatigue, adverse effects of treatment as
barriers to exercise
6 Why portions matter
7 Breakfast and water—two key tools to losing weight
8 Healthy grocery shopping—dealing with neighborhood barriers
9 Meal planning
10 Holiday eating (scheduled according to when holiday falls)
11 Stimulus control—for health promotion
12 Mindfulness for eating and cancer concerns
13 Eating away from home—restaurant and party strategies
14 Program review —where were you, where are you now?
15 Building movement into your daily life—beneﬁts of activity for
cancer and overall health risk reduction
16 Barriers to healthy eating and exercise
17 Problem solving
18 The power of habit
19 Beneﬁts of fruits and vegetables and strategies to increase
20 Where you were, where you are, and where you plan to go
21 Relapse preventioin I—what is a lapse versus relapse
22 Relapse prevention II—identifying high-risk situations
23 Relapse prevention III—maintaining a physically active lifestyle
24 Relapse prevention IV—motivation to maintain changes
25 Transitioning from Moving Forward to being on your own
26 Graduation
NOTE: Underlying each topic was the experience and perspective of being
a breast cancer survivor.
Abbreviation: ACS, American Cancer Society.
2822 © 2017 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Stolley et al
Downloaded from ascopubs.org by University of Maryland on October 24, 2017 from 134.192.021.173
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
contact information were the most successful recruitment
mode, followed by community event presentations. Reten-
tion was 86% (n = 212) at 6 months and 84% (n = 206) at
12 months. Groups were comparable at baseline. Mean (stan-
dard deviation [SD]) age was 57.5 (10.1) years, mean (SD) BMI
was 36.1 (6.2) kg/m2, and 82% were diagnosed with stage I or II
disease; 58.1% reported having hypertension, and 23.4% re-
ported having diabetes. Participants were a mean of 6.7 years
from diagnosis and reﬂected a broad range of education and
income levels.
MFG Intervention Attendance
Participants attended an average of 55% of the 48 classes
offered. Interestingly, if women attended the ﬁrst class, their mean
attendance increased to 61%. Average attendance at the ﬁrst weekly
class, which included education, support, and supervised exercise,
was higher (75%) than that for the second class (50%), which
included supervised exercise only.
Anthropometric Outcomes
Within both groups, weight, waist and hip circumferences,
and body fat were signiﬁcantly reduced at both time points
(Table 3). Lean mass decreased slightly, but relative to total mass,
the percentage of lean mass increased. Greater attendance in MFG
was associated with greater weight losses (P = .019). Smoking was
not associated with weight loss. Between groups, MFG demon-
strated signiﬁcantly greater improvements than SG for weight and
percentage of weight loss (23.49 kg v 21.27 kg; P , .001; 3.6% v
1.4%, respectively), waist circumference (23.31 cm v 21.37 cm;
P= .028), percentage of body fat (21.44 v20.58; P, .001), fat mass
(22.87 kg v 20.93 kg; P , .001), and percentage of lean mass
(01.34 v 0.56; P = .008) at 6 months, and for weight (22.70 kg
v 21.57 kg; P , .05), percentage of body fat (20.97 v 0.35;
P= .008), and fat mass (22.19 kg v20.92 kg; P = .008) at 12months.
In terms of clinically meaningful weight losses, 68.2% of MFG
participants lost$ 3% compared with 44.4% of SG; 44.3% ofMFG
and 19% of SG lost$ 5% (P, .05). MFG showed greater losses of
lean mass (kg) compared with SG at both time points, but relative
Table 2. Characteristics for the African American Breast Cancer Survivors Participating in Moving Forward: A Behavioral Weight Loss Intervention
Variable
Group
P
Total
N = 246
No. (%)
1 Intervention
n = 125
No. (%)
2 Control
n = 121
No. (%)
Age, years .308*
No. 246 125 121
Mean 6 SD 57.5 6 10.1 56.8 6 10.0 58.1 6 10.1
Menopausal status .921†
Postmenopausal 214 (87.0) 109 (87.2) 105 (86.8)
Education .399†
Some HS, HS grad, GED 59 (24.0) 24 (19.2) 35 (28.9)
Some college, associate’s degree, 2-year certiﬁcate 93 (37.9) 48 (38.4) 45 (37.2)
College graduate 47 (19.1) 24 (19.2) 23 (19.0)
Graduate or professional degree 47 (19.1) 29 (23.2) 18 (14.9)
Combined family income, last 12 months, $ .208†
, 20,000 58 (23.6) 30 (24.0) 28 (23.1)
20,000-39,999 56 (22.8) 25 (20.0) 31 (25.6)
40,000-59,999 48 (19.5) 20 (16.0) 28 (23.1)
60,000-79,999 33 (13.4) 18 (14.4) 15 (12.4)
$ 80,000 50 (20.3) 32 (25.6) 18 (14.9)
Missing 1 (0.4) 0 (0.0) 1 (0.8)
BMI, kg/m2 .564*
Mean 6 SD 36.1 6 6.2 35.9 6 6.2 36.4 6 6.4
Missing 0 0 0
Stage .187†
I 85 (38.3) 51 (44.0) 34 (32.1)
II 98 (44.1) 46 (39.7) 52 (49.1)
III 39 (17.6) 19 (16.4) 20 (18.9)
Missing 24 9 15
Currently receiving endocrine therapy .757†
No 169 (70.4) 87 (71.3) 82 (69.5)
Missing 6 3 3
Treatment
Surgery 240 (99.6) 122 (100.0) 118 (99.2) .310†
Radiation 191 (79.3) 91 (74.6) 100 (84.0) .071†
Chemotherapy 177 (73.4) 88 (72.1) 89 (74.8) .640†
Missing 5 3 2
Current smoker .511†
No 202 (91.4) 101 (90.2) 101 (92.7)
Missing 25 13 12
Abbreviations: BMI, body mass index; HS, high school; SD, standard deviation.
*t test.
†x2 test.
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lean mass increased more in MFG. No between-group differences
were noted for hip circumference.
Behavioral Outcomes
Within-group improvements were signiﬁcant for moderate
activity, daily energy intake, ﬁber, sodium, and added sugars in both
groups at 6 and 12months (Table 4; P, .05). MFG participants also
showed improvements for percentage of calories from fat, fruits, and
vegetables at 6 months and for vigorous activity and meat at 6 and
12 months (P , .01). SG participants had decreased meat intake at
12 months only (P , .001), but no changes were observed in
vigorous activity, fruit intake, or vegetable intake at either time point.
Between groups, MFG showed greater beneﬁcial changes for vig-
orous activity, daily energy intake, ﬁber intake, and added sugars at
both time points (P , .05). More MFG compared with SG par-
ticipants (64.9% v 44.6% at 6 months; P = .003; 65.4% v 52.0% at
12 months; P , .05) engaged in . 150 minutes of weekly physical
activity, a benchmark associated with improved health outcomes.37
Groups did not differ on percentage of calories from fat, fruits,
vegetables, or meat at any point. No adverse events were reported.
In summary, to our knowledge, the Moving Forward study is
the ﬁrst fully powered intervention trial to examine a targeted
weight loss intervention’s effects on anthropometrics, body
composition, and behavioral outcomes among AABCS. By design,
both groups showed positive changes. However, MFG demon-
strated signiﬁcantly greater improvements for weight, percentage
of weight loss, waist circumference, body fat and lean mass, vig-
orous activity, daily energy intake, ﬁber, sodium, and added sugars
postintervention; beneﬁts remained for weight, body fat and per-
centage of lean body mass, vigorous activity, ﬁber, and added sugars
at the 12-month follow-up.
Overweight and obesity in breast cancer survivors is associ-
ated with increased risk of all-cause mortality, breast cancer
mortality, recurrence, and comorbidities. Weight management is
particularly crucial for AABCS, given the high rates of obesity-
related comorbidities. For ethical reasons, Moving Forward was
intended to induce weight loss in both study groups, However,
MFG participants lost more than twice as much as SG participants.
This level of weight loss is superior to that reported in the few
studies conducted with AABCS and in most trials with AAwomen
in the general population.21,23,38,39 For example, two 12-week pilot
intervention studies with AABCS reported mean weight losses of
below 1 kg.21,23 In keeping with the literature showing racial
differences in weight loss in noncancer populations, mean weight
loss in our study was lower than that reported in many trials with
white breast cancer survivors.15,40-42
Currently, weight loss benchmarks associated with reduction
in breast cancer mortality or recurrence are not established.14
However, in 2013, an expert panel formed by the National In-
stitutes of Health provided graded evidence statements noting that
weight loss beginning at 3% (for glycemic measures and tri-
glycerides) and 5% (for blood pressure, HDL and LDL cholesterol)
should be considered clinically meaningful.37,43,44 It is encouraging
that mean percentage of weight loss for MFG (3.6%) met the lower
benchmark and that 44% of participants lost at least 5% (com-
pared with 19% of SG participants). To encourage larger weight
losses in future trials, emphasis and consideration should be given to
the recommended energy prescription. A 2014 study examining
differential weight loss among white and AA women receiving
identical interventions found that despite equivalent adherence be-
tween groups, AA women lost an average of 3.6 kg less than white
women.45 The authors concluded that the lower energy requirement
observed among AA women suggested that they required a lower
energy prescription to support weight losses equivalent to that of
white participants. Per theMoving Forward intervention prescription,
the MFG demonstrated a mean caloric deﬁcit of over 500 kcal and a
signiﬁcant increase in moderate and vigorous physical activity. Al-
though greater deﬁcits would lead to greater weight losses, difﬁculty
maintaining the changes should be balanced with the advantages of
smaller lifestyle changes that may be more easily maintained.
Despite the modest weight loss, both groups showed signif-
icant improvements in body fat (% and kg) and central adiposity.
This is the ﬁrst study to examine body composition changes in
a weight loss trial with AABCS using dual-energy x-ray absorp-
tiometry, a more precise methodology. These ﬁndings have im-
portant implications for potential biologic pathways associated
with breast cancer recurrence and comorbidities. Reductions in
weight, body fat, and waist circumference reduce inﬂammation
and insulin resistance, which are associated with reduced risk of
breast cancer recurrence andmultiple chronic health conditions.14,15
Compared with available data primarily from white breast cancer
survivors, our study showed smaller changes, likely relative to the
amount of weight lost.46-48 Future studies will examine the asso-
ciations between body composition changes and biomarkers of
overall health and breast cancer recurrence in AABCS.42 This is
a signiﬁcant limitation in the current literature onweight loss in AAs
in the general population as well.20We also observed small leanmass
(kg) losses in theMFG group.Weight reduction by caloric restriction
alone often leads to lean mass losses that can be associated with
sarcopenia and unfavorable metabolic proﬁles.46 Integrating re-
sistance exercise/strength training into weight management in-
terventions can preclude such losses. Importantly we did not detect
any sarcopenia at the beginning and end of our trial. In fact, we
observed increases in percentage of lean mass, with greater im-
provements noted for MFG. This is likely owing to the twice-weekly
exercise classes that included at least 20 minutes of strength training.
Although most participants had little experience with strength
training, they were interested in understanding why such training
mattered for health and quality of life. Participants were also eager to
monitor their progress. Informal strength assessments were con-
ducted at the beginning, midway through, and at the end of the
6 months. These assessments provided motivation for maintaining
and/or increasing efforts.
Within-group anthropometric and behavioral improvements
remained at the 12-month follow-up, but most attenuated com-
pared with those observed immediately postintervention for MFG
participants. These ﬁndings highlight the need for ongoing support
and accountability during the maintenance phase. Although we
provided informational newsletters to all participants (MFG and
SG), MFG participants were accustomed to class participation and
support. These results underscore the need for and interest in
health promotion resources among AABCS, which can be accessed
easily and affordably. Interestingly, SG participants continued to
show subtle improvements from baseline to the 12-month follow-
up for many outcomes. Conceivably, the minimal contact provided
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via newsletters promoted behavioral changes that led to continued,
albeit small, weight reductions.
Strengths of the current study include the randomized design,
a focus on an understudied group with a history of disparate health
outcomes, recruitment of a diverse study sample (age, education,
income), a culturally informed intervention developed with the
targeted population, high retention, and the inclusion of body
compositionmeasurements. Although all study measures were well
validated, diet and physical activity data were based on self-report.
Additional limitations included selection bias, lack of a true control
group, and limited generalizability because only AABCS were
engaged. Also, because we did not expect changes in the SG group,
we did not collect data on their engagement with study materials.
In conclusion, the Moving Forward weight loss trial supports
the efﬁcacy of an interventionist-guided and a self-guided weight
loss program for AABCS. However, the interventionist-guided pro-
gram led to greater weight loss than other studies involving AABCS,
and a subset met the intended goal of 5%. Notably, Moving Forward
was conducted collaboratively within public recreation system facil-
ities. As the cancer survivor population grows, ongoing community-
based programs that support healthy lifestyles are required. This is
particularly true for AABCS, who have high rates of obesity, often live
in resource-poor neighborhoods, and face multiple barriers to healthy
lifestyles.
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